ABBVIE INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 168.4 USD | -0.10% |
|
+7.84% | +8.78% |
| 12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
| Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
168.6
USD
Average target price
183
USD
Spread / Average Target
+8.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.78% | 298B | |
| +43.64% | 754B | |
| +41.01% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +18.66% | 250B | |
| +12.22% | 217B | |
| -0.53% | 216B | |
| +6.13% | 164B | |
| +0.03% | 163B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- BofA Securities Raises AbbVie Price Target to $165 From $160, Maintains Neutral Rating
